FDA Approves Obecabtagene Autoleucel for Adults with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukaemia By Ogkologos - December 3, 2024 697 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the FELIX study Source RELATED ARTICLESMORE FROM AUTHOR Noninferiority of OS with 3 Months Compared to 6 Months of Adjuvant Chemotherapy for Patients with High-Risk Stage III Colorectal Cancer Patient Guide on Bone Health in Cancer Now Available Also in French Lung Cancer Death Rates Among Women in Europe Are Finally Levelling Off MOST POPULAR Mom Births Stillborn Baby But Never Anticipated Nurse’s Remark She Will... March 15, 2019 CAR22 Shows Durable Efficacy After a Single Infusion in Patients with... July 25, 2024 New reports show staff shortages continue to hold back cancer care June 9, 2022 Increased Efficacy of Pembrolizumab or Pembrolizumab-Chemotherapy with Increasing PD-L1 Expression in... April 11, 2022 Load more HOT NEWS Announcing ‘Cancer Revolution’ – a world-first exhibition to engage people with... The art of practicing sustainable science 2021/22 in review: Charity looks to the future with ambitious new... Fruquintinib Prolongs Survival Compared with Placebo in Heavily Pretreated Patients with...
